Intercept Pharmaceuticals (New York, NY) a clinical-stage small molecule drug company focused on modulation of bile acid signaling in primary biliary cirrhosis and type II diabetics with fatty acid liver disease, closed a $25M Series B financing. Participants include Genextra.